Optimizing stability during the formulation of therapeutic proteins

Monoclonal antibodies and therapeutic proteins for vaccines require extensive stability characterization during their development phase to improve their probability of successful treatment. We will discuss several case studies that demonstrate how the robust intrinsic fluorescence (nanoDSF) and dynamic light scattering (DLS) data obtained from NanoTemper’s Prometheus instruments helped many groups find better formulations and storage buffers to ultimately expedite the lab to clinic pipeline.

Previous Video
Mischievous membrane proteins (and how to tame them)
Mischievous membrane proteins (and how to tame them)

Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to char...

Up next
Understanding the nuances of targeted protein degradation
Understanding the nuances of targeted protein degradation

Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquiti...